- Notification that Annual Report will be submitted late (NT 10-K)
30 Juin 2009 - 8:49PM
Edgar (US Regulatory)
|
|
|
|
|
:
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
|
|
OMB APPROVAL
|
|
|
OMB Number: 3235-0058
Expires: April 30, 2009
Estimated average burden
hours per response . . . 2.50
|
|
|
|
|
|
SEC FILE
NUMBER
|
|
|
|
|
|
CUSIP NUMBER
|
|
|
|
|
|
(Check One)
|
|
x
Form 10-K
¨
Form
20-F
¨
Form 11-K
¨
Form 10-Q
¨
Form 10-D
¨
Form N-SAR
¨
Form
N-CSR
|
|
|
|
|
For Period Ended:
March 31, 2009
|
|
|
|
|
¨
Transition Report on Form 10-K
|
|
|
¨
Transition Report on Form 20-F
|
|
|
¨
Transition Report on Form 11-K
|
|
|
¨
Transition Report on Form 10-Q
|
|
|
¨
Transition Report on Form N-SAR
|
|
|
|
|
For the Transition Period Ended:
|
|
Read Instruction (on back page) Before
Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any
information contained herein.
|
If the notification relates to a portion of
the filing checked above, identify the Item(s) to which the notification relates:
PART I REGISTRANT INFORMATION
|
|
GEOPHARMA, INC.
|
Full Name of Registrant
|
|
|
Former Name if Applicable
|
|
6950 Bryan Dairy Road
|
Address of Principal Executive Office
(Street and Number)
|
|
Largo, FL 33777
|
City, State and Zip Code
|
PART II RULES 12b-25(b) AND (c)
If the subject
report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
|
|
|
|
|
x
|
|
(a)
|
|
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
¨
|
|
(b)
|
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth
calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the
prescribed due date; and
|
¨
|
|
(c)
|
|
The accountants statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report
or portion thereof, could not be filed within the prescribed time period.
(Attach Extra Sheets if Needed)
Awaited accountants clearance in addition to the 10-K Filing Queue. Form 10-K filed June 29, 2009 at 5:45 pm once accountants clearance was gained.
PART IV OTHER INFORMATION
(1)
|
Name and telephone number of person to contact in regard to this notification
|
|
|
|
|
|
Carol Dore-Falcone
|
|
(727)
|
|
544-8866
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
¨
Yes
¨
No
|
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be
included in the subject report or portion thereof?
¨
Yes
x
No
|
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
|
GEOPHARMA, INC.
|
(Name of Registrant as Specified in Charter)
|
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date
|
|
June 30, 2009
|
|
By
|
|
/s/ Carol Dore-Falcone, as SR VP/CFO
|
|
|
|
|
|
|
Name and Title
|
INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized
representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of
the representatives authority to sign on behalf of the registrant shall be filed with the form.
|
|
|
|
|
|
|
ATTENTION
|
|
|
|
|
|
|
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).
|
Geopharma (NASDAQ:GORX)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Geopharma (NASDAQ:GORX)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024